
TOFA signals fat-burning in mice without muscle loss, hinting at a GLP-1 combo therapy
A new experimental compound called TOFA increased energy expenditure by up to 18% in mice without reducing appetite or increasing activity, and it also blocks two enzymes involved in fat and cholesterol production. Unlike GLP-1 drugs (Ozempic/Wegovy/Zepbound), which can cause lean muscle loss during rapid weight loss, TOFA could enable fat loss while preserving muscle and might be used alongside GLP-1 therapies. The findings are early and limited to animals, with human trials not yet underway.
